Prime Minister invests €10 million in animal-based business alongside farmers' alliance
In a significant development for the European farming sector, Belgian biotech company Animab has developed an antibody named Nanoprotec to combat gastrointestinal infections in pigs. This innovative product, which targets enterotoxigenic Escherichia coli (ETEC F4), a leading cause of diarrhoea in piglets, is set to offer farmers an antibiotic-free alternative to current medication.
The investment community has shown confidence in Animab's solution, with the company securing €10 million in funding from PMV, AIF, QBIC, Seventure Partners, and Laboratory group Anacura. Kenneth Wils, head of life sciences and care at PMV, considers Animab's innovation to be revolutionary and exactly the type of innovation the European farming sector needs.
Felix Van Camp, a business strategist at Anacura, expressed similar enthusiasm about investing in Animab. He cited the proven credibility of Animab's leadership as a factor in the investment decision, as well as the strength of Nanoprotec and Animab's promising pipeline.
The product, given to piglets in their drinking water, prevents bacterial adhesion to the intestinal wall, neutralising potentially harmful pathogens. The European Union backs Animab under its InvestEU programme.
As for the commercial launch and regulatory approval timeline for Nanoprotec, there is no publicly available information from search results regarding these details. However, Animab has announced that Nanoprotec will be sent to the European Medicines Agency for regulatory submission before the end of this year, with a product launch planned for the end of 2026.
The funding secured by Animab will be used for the commercial launch of the oral antibody and the advancement of its product pipeline. The investment comes at a critical time, as antimicrobial resistance, which may lead to 22 million deaths annually by 2050, poses a rising threat to global public health.
For those seeking detailed and up-to-date information about Nanoprotec's approval process and launch schedule, it is recommended to check Animab's official announcements, their website, industry press releases, or veterinary pharmaceutical regulatory filings.
- The private equity firms PMV, AIF, QBIC, Seventure Partners, and Labgroup Anacura have shown their belief in financial inclusion of innovation in the agriculture sector, as they collectively invested €10 million in Animab, a Beligian biotech company.
- The innovative product, Nanoprotec, developed by Animab, targets enterotoxigenic Escherichia coli (ETEC F4), a leading cause of diarrhea in piglets, providing farmers with an antibiotic-free alternative to current medication in the health-and-wellness sector.
- Kenneth Wils, head of life sciences and care at PMV, deems Animab's innovation revolutionary and considers it crucial for the future growth and development of the European farming sector.
- The European Union supports Animab's endeavors under its InvestEU program, recognizing the importance of science and technology in addressing real-world challenges such as antimicrobial resistance, which could claim 22 million lives annually by 2050.
- In the coming years, Animab plans to launch Nanoprotec, an oral antibody, in the global market and continue investing in its product pipeline, with the aim of creating a substantial impact in the finance and venture capital sectors.
- On the heels of its successful €10 million funding round, Animab is poised to make in-roads in the fitness-and-exercise segment as it reshapes the agricultural landscape through investing in cutting-edge health-and-wellness solutions.
